383 related articles for article (PubMed ID: 30855374)
1. Trimodality therapy for bladder cancer: modern management and future directions.
Pham A; Ballas LK
Curr Opin Urol; 2019 May; 29(3):210-215. PubMed ID: 30855374
[TBL] [Abstract][Full Text] [Related]
2. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
3. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.
Jiang DM; Chung P; Kulkarni GS; Sridhar SS
Curr Oncol Rep; 2020 Feb; 22(2):14. PubMed ID: 32008105
[TBL] [Abstract][Full Text] [Related]
4. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
Arcangeli G; Strigari L; Arcangeli S
Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
[TBL] [Abstract][Full Text] [Related]
5. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
6. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Johnson SB; Yu JB
Curr Oncol Rep; 2018 Jun; 20(9):66. PubMed ID: 29959582
[TBL] [Abstract][Full Text] [Related]
7. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
8. Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Konieczkowski DJ; Efstathiou JA; Mouw KW
Hematol Oncol Clin North Am; 2021 Jun; 35(3):567-584. PubMed ID: 33958151
[TBL] [Abstract][Full Text] [Related]
9. Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.
El-Achkar A; Souhami L; Kassouf W
Curr Urol Rep; 2018 Nov; 19(12):108. PubMed ID: 30392150
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).
Arcangeli G; Arcangeli S; Strigari L
Crit Rev Oncol Hematol; 2015 Apr; 94(1):105-15. PubMed ID: 25541350
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
[TBL] [Abstract][Full Text] [Related]
13. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO
World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218
[TBL] [Abstract][Full Text] [Related]
14. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
15. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.
Mitin T; Shipley WU; Efstathiou JA; Heney NM; Kaufman DS; Lee RJ; Zietman AL
Curr Urol Rep; 2013 Apr; 14(2):109-15. PubMed ID: 23341373
[TBL] [Abstract][Full Text] [Related]
16. Trimodality therapy in bladder cancer: who, what, and when?
Premo C; Apolo AB; Agarwal PK; Citrin DE
Urol Clin North Am; 2015 May; 42(2):169-80, vii. PubMed ID: 25882559
[TBL] [Abstract][Full Text] [Related]
17. Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer.
Broughman JR; Vuong W; Mian OY
Curr Treat Options Oncol; 2020 Nov; 22(1):3. PubMed ID: 33230599
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
[TBL] [Abstract][Full Text] [Related]
19. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?
Mathieu R; Lucca I; Klatte T; Babjuk M; Shariat SF
Curr Opin Urol; 2015 Sep; 25(5):476-82. PubMed ID: 26125510
[TBL] [Abstract][Full Text] [Related]
20. [Combined therapy for patients with invasive bladder cancer].
Startsev VIu; Karelin MI
Vopr Onkol; 2003; 49(2):235-8. PubMed ID: 12785212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]